CN111836623A - 诱导三重基序包含蛋白16(trim16)信号传导的组合物和方法 - Google Patents

诱导三重基序包含蛋白16(trim16)信号传导的组合物和方法 Download PDF

Info

Publication number
CN111836623A
CN111836623A CN201980018082.3A CN201980018082A CN111836623A CN 111836623 A CN111836623 A CN 111836623A CN 201980018082 A CN201980018082 A CN 201980018082A CN 111836623 A CN111836623 A CN 111836623A
Authority
CN
China
Prior art keywords
cancer
nucleic acid
rna
uuuuuuuuuu
trim16
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980018082.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·J·小盖尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of CN111836623A publication Critical patent/CN111836623A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201980018082.3A 2018-02-02 2019-02-01 诱导三重基序包含蛋白16(trim16)信号传导的组合物和方法 Pending CN111836623A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862625623P 2018-02-02 2018-02-02
US62/625,623 2018-02-02
PCT/US2019/016413 WO2019152884A1 (en) 2018-02-02 2019-02-01 Compositions and methods for inducing tripartite motif-containing protein 16 (trim16) signaling

Publications (1)

Publication Number Publication Date
CN111836623A true CN111836623A (zh) 2020-10-27

Family

ID=67479930

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980018082.3A Pending CN111836623A (zh) 2018-02-02 2019-02-01 诱导三重基序包含蛋白16(trim16)信号传导的组合物和方法

Country Status (9)

Country Link
US (1) US20210046168A1 (https=)
EP (1) EP3746088B1 (https=)
JP (1) JP7409612B2 (https=)
KR (1) KR102828978B1 (https=)
CN (1) CN111836623A (https=)
AU (1) AU2019215191B2 (https=)
BR (1) BR112020015821A2 (https=)
RU (1) RU2020128838A (https=)
WO (1) WO2019152884A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11679163B2 (en) 2019-09-20 2023-06-20 Hdt Bio Corp. Compositions and methods for delivery of RNA
WO2021067480A1 (en) * 2019-10-02 2021-04-08 University Of Washington Compositions and methods for treatment of hepatitis b virus infection
WO2021097347A1 (en) * 2019-11-15 2021-05-20 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
KR20220156933A (ko) 2020-03-23 2022-11-28 에이치디티 바이오 코포레이션 Rna의 전달을 위한 조성물 및 방법
EP4112665A4 (en) * 2020-03-27 2024-04-10 Mitsui Chemicals, Inc. LIGHT-CURING COMPOSITION, CURED PRODUCT AND DENTAL PRODUCT
AU2022302143A1 (en) 2021-07-02 2024-01-18 Yale University Compositions and methods for treating cancers
EP4395832A1 (en) 2021-08-31 2024-07-10 Yale University Compositions and methods for treating cancers
EP4404919A4 (en) 2021-09-22 2025-08-20 Hdt Bio Corp DRIED NANOPARTICLE COMPOSITIONS
JP2024535354A (ja) 2021-09-22 2024-09-30 エイチディーティー バイオ コーポレーション がん治療組成物およびその使用
WO2023048760A1 (en) 2021-09-22 2023-03-30 Hdt Bio Corp. Rna vaccines against infectious diseases
CA3232719A1 (en) 2021-09-22 2023-03-30 Steven Gregory REED Sars-cov-2 rna vaccine compositions and methods of use
US20230303719A1 (en) 2022-03-03 2023-09-28 Yale University Humanized 3e10 antibodies, variants, and antigen binding fragments thereof
WO2026039779A1 (en) 2024-08-15 2026-02-19 Yale University Humanized 3e10 antibodies and antigen binding fragments optimized for rad51 binding

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150017207A1 (en) * 2013-07-09 2015-01-15 University Of Washington Through Its Center For Commercialization Methods and Compositions for Activation of Innate Immune Responses Through RIG-I Like Receptor Signaling

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003078595A2 (en) * 2002-03-15 2003-09-25 Astral, Inc. Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response
ES2911034T3 (es) 2006-08-08 2022-05-17 Univ Bonn Rheinische Friedrich Wilhelms Estructura y uso de oligonucleótidos 5' fosfato
BRPI1100857A2 (pt) * 2011-03-18 2013-05-21 Eduardo Nowill Alexandre agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
WO2016179034A2 (en) * 2015-05-01 2016-11-10 The Trustees Of The University Of Pennsylvania Methods and compositions for stimulating immune response using potent immunostimulatory rna motifs
MA44252A (fr) * 2016-02-16 2018-12-26 Harvard College Vaccins contre des agents pathogènes et leurs procédés de production et d'utilisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150017207A1 (en) * 2013-07-09 2015-01-15 University Of Washington Through Its Center For Commercialization Methods and Compositions for Activation of Innate Immune Responses Through RIG-I Like Receptor Signaling

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
G. HARTMANN等: "Nucleic Acid Immunity" *
PATRICK Y. KIM等: "TRIM16 overexpression induces apoptosis through activation of caspase-2 in cancer cells" *

Also Published As

Publication number Publication date
EP3746088B1 (en) 2024-07-10
KR102828978B1 (ko) 2025-07-02
BR112020015821A2 (pt) 2021-03-09
AU2019215191A1 (en) 2020-09-17
JP7409612B2 (ja) 2024-01-09
EP3746088A4 (en) 2023-02-22
EP3746088A1 (en) 2020-12-09
KR20200116976A (ko) 2020-10-13
EP3746088C0 (en) 2024-07-10
WO2019152884A1 (en) 2019-08-08
AU2019215191B2 (en) 2025-08-14
US20210046168A1 (en) 2021-02-18
JP2021512123A (ja) 2021-05-13
RU2020128838A (ru) 2022-03-03

Similar Documents

Publication Publication Date Title
JP7409612B2 (ja) トリパタイトモチーフ含有蛋白質１６（ｔｒｉｍ１６）シグナル伝達を誘導するための組成物及び方法
Lin et al. A role for casein kinase II phosphorylation in the regulation of IRF-1 transcriptional activity
Bavelloni et al. AKT‐dependent phosphorylation of the adenosine deaminases ADAR‐1 and‐2 inhibits deaminase activity
AU2020283323A1 (en) Treatment of ALT cancers
CN112996802B (zh) 用于制备抗肿瘤沙粒病毒的方法以及沙粒病毒突变体
Chengcheng et al. IFI16 plays a critical role in avian reovirus induced cellular immunosuppression and suppresses virus replication
CA3147640A1 (en) Second generation seneca valley virus oncolytic therapy: compositions and methods thereof
Miyamoto et al. Theilovirus 3C Protease Cleaves the C-Terminal Domain of the Innate Immune RNA Sensor, Melanoma Differentiation–Associated Gene 5, and Impairs Double-Stranded RNA–Mediated IFN Response
WO2013047941A1 (ko) 비소세포성 폐암에서 ｔｍ４ｓｆ４의 발현 또는 활성의 조절을 통한 방사선 저항성 및 암세포의 성장, 전이, 및 침윤능력을 저하시키는 방법
WO2019117188A1 (ja) 細胞増殖抑制剤及びそれを含むがんの治療若しくは予防用医薬組成物
US9296994B2 (en) Archease as RNA ligaes complex member
JP2004180540A (ja) 哺乳動物のＴｏｌｌ様受容体３に結合する新規アダプタータンパク質およびその遺伝子
WO2022037666A1 (zh) Rdr蛋白在肿瘤治疗中的应用
JP6839707B2 (ja) Ｇｐｒ１６０を過剰発現する癌の予防、診断および治療
CN106319020B (zh) p97基因治疗病毒感染的用途及其相关药物
Xu et al. Construction of a recombinant pIRES2-EGFP-ARTS plasmid and its effect on LX-2 cells
HK40122461A (zh) 用於制备抗肿瘤沙粒病毒的方法以及沙粒病毒突变体
JP2003221349A (ja) ｐ７３のアポトーシス誘導調節剤
WO2023077133A2 (en) Controlling homeostatic regulatory circuitry in hypothalamus
JP2024522850A (ja) 遺伝子の発現をモジュレートするための組成物および方法
HK40054624B (zh) 用於制备抗肿瘤沙粒病毒的方法以及沙粒病毒突变体
CN120789264A (zh) Snip1蛋白301位点为靶点在制备或筛选抗三阴乳腺癌药物中的应用
Stellacci I B Kinase Targets Interferon Regulatory Factor 1 in Activated T Lymphocytes
by Interferon Differential Regulation of Human Interferon
Morrow Examining the Role of STATs and STAT Signaling the Induction, Enhancement, and Prolonged Duration of Antiviral Activity by IFN-γ and IFN-α2a in Combination with Ribavirin

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination